These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28891048)

  • 1. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
    Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
    Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.
    Li B; Li L; Li X; Wang Y; Xie Y; Liu C; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8563-7. PubMed ID: 26339434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
    Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
    J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
    Jour G; Scarborough JD; Jones RL; Loggers E; Pollack SM; Pritchard CC; Hoch BL
    Hum Pathol; 2014 Aug; 45(8):1563-71. PubMed ID: 24908143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.
    Zheng B; Qu Y; Wang J; Shi Y; Yan W
    Cancer Genomics Proteomics; 2019; 16(3):221-228. PubMed ID: 31018952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
    Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
    Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma.
    Nakayama R; Nemoto T; Takahashi H; Ohta T; Kawai A; Seki K; Yoshida T; Toyama Y; Ichikawa H; Hasegawa T
    Mod Pathol; 2007 Jul; 20(7):749-59. PubMed ID: 17464315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
    Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
    Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.
    Roland CL; May CD; Watson KL; Al Sannaa GA; Dineen SP; Feig R; Landers S; Ingram DR; Wang WL; Guadagnolo BA; Feig B; Hunt KK; Cormier JN; Lazar AJ; Torres KE
    Ann Surg Oncol; 2016 Jul; 23(7):2220-8. PubMed ID: 26847678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MFH and high-grade undifferentiated pleomorphic sarcoma-what's in a name?
    Delisca GO; Mesko NW; Alamanda VK; Archer KR; Song Y; Halpern JL; Schwartz HS; Holt GE
    J Surg Oncol; 2015 Feb; 111(2):173-7. PubMed ID: 25219789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
    Crago AM; Cardona K; Koseła-Paterczyk H; Rutkowski P
    Surg Oncol Clin N Am; 2022 Jul; 31(3):419-430. PubMed ID: 35715142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma.
    Song B; Lee K; Lee C; Moon KC
    Pathol Int; 2018 Sep; 68(9):509-516. PubMed ID: 30094896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions.
    Dineen SP; Roland CL; Feig R; May C; Zhou S; Demicco E; Sannaa GA; Ingram D; Wang WL; Ravi V; Guadagnolo A; Lev D; Pollock RE; Hunt K; Cormier J; Lazar A; Feig B; Torres KE
    Ann Surg Oncol; 2015 Nov; 22(12):3913-20. PubMed ID: 25743327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
    Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
    Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytopathology of myxofibrosarcoma: a study of 66 cases and literature review.
    Wakely PE
    J Am Soc Cytopathol; 2021; 10(3):300-309. PubMed ID: 33041221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.
    Vodanovich DA; Spelman T; May D; Slavin J; Choong PFM
    ANZ J Surg; 2019 Sep; 89(9):1045-1050. PubMed ID: 31364245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.